Kaneka Corporation on 19/09/2012 (Osaka, Japan, President: Kimikazu
Sugawara) announces the launch of KANEKA KanCapA, a new Protein A
Chromatography Resin for the purification of therapeutic antibodies.
"KANEKA KanCapA" exhibits high antibody adsorbing capacity and alkaline
resistance.
Therapeutic antibodies represent an innovative class of drugs used to
treat a wide range of diseases such as rheumatoid arthritis and cancer.
Protein A chromatography resin is widely used in the production of
therapeutic antibodies due to its high affinity and excellent
selectivity for antibodies. Utilizing our expertise in protein design
and genetic engineering, we have made significant improvements to 'Wild
type' or "Native' Protein A ligand. Immobilization of our improved
Protein A ligand to highly cross-linked cellulose beads allows KANEKA
KanCapA to exhibit alkaline resistance, stability over repeated cycle
use, and to be used at high flow rates from laboratory to industrial
scale with high binding capacity.
As a result of positive feedback and evaluation results from our
customers we are pleased to announce the commercialization and sales of
KANEKA KanCapA in October 2012. We will introduce KANEKA KanCapA at
BioProcess International (Oct. 8th - 12th,
Providence RI, USA) and at CPhI Worldwide (Oct. 9th-11th,
Madrid, Spain). Our expectation is that the excellent properties of
KANEKA KanCapA will allow customers to develop stable, streamlined and
cost effective antibody purification processes.
In addition we are investing our research and technology resources
towards the development of the next generation chromatography resins
having the high quality and novel performance for the production of
biopharmaceuticals. Along with our group companies, Eurogentec S.A.
(Liege, Belgium) for contract manufacturing of biopharmaceuticals and
GeneFrontier Corporation (Chiba, Japan) for drug candidate exploration,
KANEKA will continue to offer technical and cost effective solutions in
the field of biopharmaceuticals.
Study reveals protein plaques in neurodegeneration function as enzymes, breaking down ATP